Amgen Names David Beier Senior Vice President, Global Government Affairs
THOUSAND OAKS, Calif., Dec. 9 -- Amgen Inc.
(Nasdaq: AMGN), the world's largest biotechnology company, today announced
that David Beier has been named senior vice president, Global Government
Affairs. Beier will be responsible for the operations of Amgen's Washington,
D.C. office and the management of corporate regulatory and legislative issues.
Beier joins Amgen from the law firm of Hogan and Hartson in Washington,
D.C. where he was a partner representing clients in the health care and
technology fields, including pharmaceutical and biotechnology firms. He has
an extensive government affairs and public policy background, and previously
served as chief domestic policy advisor to the Vice President of the United
States from 1998 to early 2001. He also held positions as vice president of
government affairs and public policy for Genentech and staff counsel in the
U.S. House of Representatives. Beier holds a J.D. from Albany Law School and
a bachelor's degree from Colgate University.
"Drawing upon his strong government and industry experience, David will
make a significant contribution to aligning Amgen's commercial interests with
government affairs activities, as well as strengthening our presence in
capitols at the federal, state and international level, " said George Morrow,
Amgen's executive vice president of Global Commercial Operations.
Beier replaces Pete Teeley, who is assuming a new role as government
affairs advisor for Amgen. Teeley also has an extensive government affairs
background. He founded Amgen's Washington, D.C. office and has done an
outstanding job leading Amgen's government affairs efforts over the past
10 years. Prior to joining Amgen, he held a variety of public positions in
the 1980s, including serving as U.S. Ambassador to Canada and as Press
Secretary and Assistant to the Vice President of the United States.
"Working to ensure that patients have access to our products and that our
innovation in health care continues because we are able to receive the proper
reimbursements for our therapies is a key task in achieving our corporate
goals," Morrow said. "Amgen is fortunate to have these two high-caliber
professionals leading a highly professional Washington staff in this effort."
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on advances in
cellular and molecular biology.
CONTACT: Amgen, Thousand Oaks
Media, (805) 447-4587
Investors, (805) 447-1060